Aurobindo Pharma Limited today announced its consolidated financial results for the quarter ended September 30, 2024. Aurobindo Pharma reported a strong overall performance for the Q2FY25. The company’s formulation revenue increased by 11.3% year-on-year (YoY) to ₹6,640 crore, reflecting continued growth across various segments. US Formulations The US formulations segment continued to be a key …